Phase 2 study of weekly bortezomib in mantle cell and follicular lymphoma
about
Noxa/Bcl-2 protein interactions contribute to bortezomib resistance in human lymphoid cellsClinical activity of bortezomib in relapsed/refractory MALT lymphomas: results of a phase II study of the International Extranodal Lymphoma Study Group (IELSG).Bortezomib may be safely combined with Y-90-ibritumomab tiuxetan in patients with relapsed/refractory follicular non-Hodgkin lymphoma: a phase I trial of combined induction therapy and bortezomib consolidation.Bortezomib as salvage treatment for heavily pretreated relapsed lymphoma patients: a multicenter retrospective study.Phase II study of bortezomib in combination with rituximab, cyclophosphamide and prednisone with or without doxorubicin followed by rituximab maintenance in patients with relapsed or refractory follicular lymphoma.Phase 1 dose-escalation study of IV ixazomib, an investigational proteasome inhibitor, in patients with relapsed/refractory lymphoma.Weekly versus biweekly bortezomib given in patients with indolent non-Hodgkin lymphoma: A meta-analysisTargeted therapy in lymphoma.The combination of bendamustine, bortezomib, and rituximab for patients with relapsed/refractory indolent and mantle cell non-Hodgkin lymphomaEmerging role of carfilzomib in treatment of relapsed and refractory lymphoid neoplasms and multiple myeloma.Update on treatment of follicular non-Hodgkin's lymphoma: focus on potential of bortezomibClinical and pharmacodynamic activity of bortezomib and decitabine in acute myeloid leukemia.Arsenic trioxide rewires mantle cell lymphoma response to bortezomibPhase II trial of R-CHOP plus bortezomib induction therapy followed by bortezomib maintenance for newly diagnosed mantle cell lymphoma: SWOG S0601.Bortezomib for the treatment of non-Hodgkin's lymphomaPhase I study of azacitidine and bortezomib in adults with relapsed or refractory acute myeloid leukemia.Current treatment of mantle cell lymphoma: results of a national survey and consensus meeting.Controlled-release oxycodone for the treatment of bortezomib-induced neuropathic pain in patients with multiple myeloma.The proteasome inhibitor bortezomib targets cell cycle and apoptosis and acts synergistically in a sequence-dependent way with chemotherapeutic agents in mantle cell lymphoma.Novel agents in indolent lymphomas.Phase I trial of weekly and twice-weekly bortezomib with rituximab, cyclophosphamide, and prednisone in relapsed or refractory non-Hodgkin lymphoma.Treatment for patients with relapsed/refractory mantle cell lymphoma: European-based recommendations.Proteasome inhibitors in cancer therapy.
P2860
Q24298561-97811807-ECBA-4A1B-973D-38879C1E8A58Q33391725-F45CB2D1-D082-40C0-836B-4140EF7679B7Q33402885-1A1B1325-E1CA-4D9F-BE1A-370F1B37A2ABQ33404090-B676F467-0E14-4CBE-AECD-CBB340BE1B73Q33416533-104F0F76-64AF-4815-B0F1-B0A1C7367E84Q33418257-359F2339-8AAB-440F-8960-374B36B3417BQ33713106-30A411C8-1C6D-44E3-8DE3-27C18EE29CEDQ34413686-5E1622D1-691E-4CB1-A94E-5B925B460701Q34707136-724B21D4-0905-409E-B2DF-C2E23083B6E3Q35009005-8DC9E2FB-FD83-4E6A-B539-6D7F0F60C7A6Q35905929-8A62EFD5-A7C3-4BB0-9D3E-2E4A57DB3512Q36057877-30A139A0-F0D1-44F9-984F-F84EEF28C750Q36358595-B1467A0F-93F3-471C-AA86-9D9175AEC128Q36456078-B2CC52A7-D47D-42FD-A1F8-2D827B22954BQ36868056-A46417E1-5A63-40FD-8C2E-CE4210123333Q37587057-FCD70260-91C6-46B0-AAF5-346BB58C6DF6Q38038482-BEB2DD19-B7E4-497C-9B51-DE5F0C8E6AE6Q39246290-AA19C7A2-3380-442A-941A-490655D75899Q39414811-A557CE76-3015-4312-879E-516F1D2200F9Q39431412-944854B0-FF7F-45D6-A618-B20A02C79034Q40333043-42AA80B8-165D-4CE1-B6D9-94BD1AA318B0Q48238170-17CF28E4-B11B-451F-9ABC-1D7100F7277DQ53752929-B4BD349B-796A-407D-BE73-B60EEC5451F7
P2860
Phase 2 study of weekly bortezomib in mantle cell and follicular lymphoma
description
2009 nî lūn-bûn
@nan
2009 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
name
Phase 2 study of weekly bortezomib in mantle cell and follicular lymphoma
@ast
Phase 2 study of weekly bortezomib in mantle cell and follicular lymphoma
@en
type
label
Phase 2 study of weekly bortezomib in mantle cell and follicular lymphoma
@ast
Phase 2 study of weekly bortezomib in mantle cell and follicular lymphoma
@en
prefLabel
Phase 2 study of weekly bortezomib in mantle cell and follicular lymphoma
@ast
Phase 2 study of weekly bortezomib in mantle cell and follicular lymphoma
@en
P2093
P2860
P50
P1476
Phase 2 study of weekly bortezomib in mantle cell and follicular lymphoma
@en
P2093
Barbara M Cortelli
Carol Portlock
Craig Moskowitz
David Straus
Dorothy Lin
Ellen Neylon
Jennifer Pappanicholaou
John Gerecitano
John Wright
Otilia Dumitrescu
P2860
P304
P356
10.1111/J.1365-2141.2009.07775.X
P407
P577
2009-07-16T00:00:00Z